Abstract
Aim: To estimate treatment patterns and healthcare costs among triple-class exposed relapsed and refractory multiple myeloma (RRMM) patients. Materials & methods: Eligible patients had ≥1 line of t... Lay abstract Treatment of multiple myeloma (MM) has evolved rapidly over recent decades, with the introduction of immunomodulatory drugs, proteasome inhibitors and the anti-CD38 monoclonal antibody...
Funding Information
  • Bristol-Myers Squibb

This publication has 22 references indexed in Scilit: